ONENESS BIOTECH Business Summary

Oneness Biotech Co., Ltd. (4743.TWO) is a leading biopharmaceutical company that generates revenue through the commercialization of proprietary drug candidates, strategic out-licensing agreements, and milestone-based payments. The company’s business model is structured around two primary segments: chronic wound care, centered on its flagship botanical drug Fespixon (ON101) for diabetic foot ulcers (DFU), and an immunology pipeline featuring the siRNA-based SNS812 and the anti-IgE antibody FB825. Revenue streams are currently transitioning from R&D-driven milestone payments to high-margin product sales following regulatory approvals in key markets including China, Taiwan, and Southeast Asia. In the global advanced wound care market, Oneness competes with established players such as MediWound, Smith & Nephew, and Organogenesis, positioning itself as a disruptive innovator by utilizing a unique botanical-based R&D platform that meets rigorous international pharmaceutical standards for efficacy and safety. The company is led by Chairman Chao-You (William) Lu and President Dr. Chih-Hsien (James) Huang, both of whom bring decades of experience in pharmaceutical R&D and corporate strategy within the Asian life sciences ecosystem. Dr. Huang, a key architect of the company’s scientific advancements, has been instrumental in navigating the regulatory hurdles for botanical new drugs globally. Oneness was founded with the strategic backing of the Diamond BioFund, Taiwan’s largest life-sciences-focused venture capital fund, which remains a significant institutional shareholder. The board and investor base are further strengthened by the involvement of the Fubon Group, one of Taiwan’s premier financial conglomerates, providing the company with substantial capital access and institutional stability. This combination of academic rigor, supported by ties to Academia Sinica, and powerful financial pedigree solidifies Oneness’s position as a cornerstone of Taiwan’s biotechnology sector.